Tomoko Yoshihama

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Towards sustainable hereditary breast and ovarian cancer surveillance: insights from a single-center survey.

Towards sustainable hereditary breast and ovarian cancer surveillance: insights from a single-center survey.

Journal: Journal of human genetics

Published: March 23, 2026

Genomic, Trop-2, and Immune Profiles of Carcinomatous and Sarcomatous Components in Ovarian Carcinosarcoma.

Genomic, Trop-2, and Immune Profiles of Carcinomatous and Sarcomatous Components in Ovarian Carcinosarcoma.

Journal: Cancer reports (Hoboken, N.J.)

Published: August 05, 2025

Elimusertib exhibits strong synergy with olaparib in ovarian cancer organoids through replication fork interference.

Elimusertib exhibits strong synergy with olaparib in ovarian cancer organoids through replication fork interference.

Journal: Scientific reports

Published: July 27, 2025

The Keio HBOC Center: A Model of Hereditary Breast and Ovarian Cancer Management.

The Keio HBOC Center: A Model of Hereditary Breast and Ovarian Cancer Management.

Journal: The Keio journal of medicine

Published: June 22, 2025

A case of primary ovarian clear cell carcinoma with ETV6::NTRK3 fusion.

A case of primary ovarian clear cell carcinoma with ETV6::NTRK3 fusion.

Journal: International cancer conference journal

Published: May 03, 2025

Current Situation and Future Directions of Risk-reducing Salpingo-oophorectomy.

Current Situation and Future Directions of Risk-reducing Salpingo-oophorectomy.

Journal: The Keio journal of medicine

Published: March 25, 2025

Hormone replacement therapy in female-specific cancer survivors: considerations beyond cancer cure.

Hormone replacement therapy in female-specific cancer survivors: considerations beyond cancer cure.

Journal: Japanese journal of clinical oncology

Published: March 24, 2025

High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target.

High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target.

Journal: Cancer research communications

Published: January 17, 2025

A rare case of synchronous bilateral ovarian cancer with combined clear cell and mucinous carcinomas and brain metastases.

A rare case of synchronous bilateral ovarian cancer with combined clear cell and mucinous carcinomas and brain metastases.

Journal: International cancer conference journal

Published: December 14, 2023

Clinical availability and characteristics of multigene panel testing for recurrent/advanced gynecologic cancer.

Clinical availability and characteristics of multigene panel testing for recurrent/advanced gynecologic cancer.

Journal: International journal of clinical oncology

Published: April 26, 2023

Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer.

Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer.

Journal: International journal of clinical oncology

Published: November 12, 2021

ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.

ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.

Journal: Gynecologic oncology

Published: April 12, 2021

Showing 1-12 of 22

Last Updated: 09/26/2026